Back to Agenda
Major Reforms and Strengthened International Cooperation – What Is Happening in China?
Session Chair(s)
Carol Zhu, MBA
Vice President, Portfolio and Project Management, JW Therapeutics, China
The Chinese legal framework for medical products has undergone major reforms in the last years. The new pieces of legislation are now coming into force one by one. It is most relevant for companies to be abreast with the changes the new legislation brings for this important market. In addition, the China Food and Drug Administration has strengthened and enhanced its international cooperation. The underlying strategy as well as some recent developments will be outlined, such as the role and involvement of CFDA in ICH and ICMRA.
Speaker(s)
Xiaoling Qin
Director, Department of the Science & Technology & International Cooperation, National Medical Products Administration, China
China Regulatory Reform in Review and Approval and Global Collaboration
Xiangyu Wang
, Division Director, Department of International Cooperation, China
Xiaojun (Wendy) Yan, MD, MBA
Strategic Advisor, DIA BOD, China
New Approaches from China Regulatory Authority to Foster Innovation - Industry Perspective
Melly Lin, MS
CMC Regulatory Policy Lead, Pharma Technical Regulatory, F. Hoffmann-La Roche Ltd, Switzerland
Panel Discussion
Jessica Liu, MD
Senior Consultant, Beijing Taya Ltd, China
Panel Discussion
Have an account?